Ignite Creation Date:
2025-12-24 @ 10:29 PM
Ignite Modification Date:
2025-12-25 @ 8:03 PM
Study NCT ID:
NCT01023035
Status:
COMPLETED
Last Update Posted:
2021-02-08
First Post:
2009-11-24
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Boceprevir/Peginterferon/Ribavirin for Chronic Hepatitis C: Erythropoietin Use Versus Ribavirin Dose Reduction for Anemia (P06086 AM2)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2009-12-07
Start Date Type:
ACTUAL
Primary Completion Date:
2011-10-26
Primary Completion Date Type:
ACTUAL
Completion Date:
2011-10-26
Completion Date Type:
ACTUAL
First Submit Date:
2009-11-24
First Submit QC Date:
None
Study First Post Date:
2009-12-01
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2012-10-16
Results First Submit QC Date:
None
Results First Post Date:
2012-11-15
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-01-15
Last Update Post Date:
2021-02-08
Last Update Post Date Type:
ACTUAL